Status:
COMPLETED
High Doses of Candesartan Cilexetil on the Reduction of Proteinuria
Lead Sponsor:
AstraZeneca
Conditions:
Proteinuria
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the effects of high doses of candesartan cilexetil and also to assess which dose (16mg, 64mg, 128mg) is the most optimal for the maximum reduction of proteinuria...
Eligibility Criteria
Inclusion
- Informed consent
- Stable hypertension defined as no new antihypertensive medication started within 6 weeks of Visit 1
- Minimum 6-month history of hypertension and primary glomerular disease
- Hypertensive nephrosclerosis
- Diabetic nephropathy with stable proteinuria as defined by ≥ 1g/24 hours on more than one occasion within 6 months prior to Visit 1
Exclusion
- Persistent hypertension
- New anti-hypertensive medications started within 6 weeks of Visit 1
- Significant cardiac disease or Liver disease
- Females of childbearing potential without reliable contraception
- Pregnant women and women who are breast-feeding
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
270 Patients enrolled
Trial Details
Trial ID
NCT00242346
Start Date
April 1 2003
End Date
December 1 2006
Last Update
December 19 2007
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Calgary, Alberta, Canada
2
Research Site
Edmonton, Alberta, Canada
3
Research Site
Kelowna, British Columbia, Canada
4
Research Site
Vancouver, British Columbia, Canada